- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04449471
Naproxen Pharmacogenetic Study (Project 1, Aim 2)
Project 1: Program on Genetic and Dietary Predictors of Drug Response in Rural and AI/AN Populations (Naproxen Study)
Study Overview
Detailed Description
This pharmacogenetics study will test the hypothesis that inheritance of a M1L variant in the CYP2C9 gene, which was first discovered in Yup'ik Alaska Native people, causes complete loss of function in CYP-2C9-dependent catalytic activity.
Study participants will be selected from a cross-sectional population of >750 Yup'ik men and women, ≥18 years, for whom CYP2C9 genotype has already been determined as part of a SNP discovery study, and who consented to be contacted for future research. There will be 15 participants in each of two genotyped groups ((1) Met1/Met1 and (2) Met1/Leu1 or Leu1/Leu1), for a total of 30 participants. The two groups will be matched for sex of the participants; the proportion determined by the composition of the least frequent Leu1 carrier group. The investigators will attempt to recruit a similar range of ages in each genotyped group and the widest range possible. Recruitment will occur in one of 10 communities in the Yukon-Kuskokwim delta that participated in our original SNP discovery study.
Participants will be asked to fast overnight prior to the study and will be allowed to eat ad libitum 2 hours after naproxen is taken. A fasting 13 ml venous blood sample will be collected from each participant for isolation of DNA and plasma. Spot urine will be collected from each participant as an analytic control the morning of the blood draw. At approximately 9 am, each participant will be given a single 220-mg dose of Naproxen, by mouth, with a glass of water. The total urine output over the next 24-hour will be collected by the participant and returned to the clinic the next day. The urine volume will be measured and recorded and two 5 mL aliquots will be frozen at -80°C and stored for unchanged drug and metabolite analysis analyses.
Total (conjugated and unconjugated) 6-O-Desmethyl naproxen and unchanged naproxen concentrations in urine will be measured by LC-MS/MS. A ratio of the total 6-O-desmethyl naproxen/naproxen (M/P) excreted in urine over 24-hours will be computed. 6-O-desmethyl naproxen is formed selectively by CYP2C9.
Pairwise comparison of the mean M/P ratios, assuming unequal variance, will be evaluated using a t-test to determine if there are significant differences in activity for carriers of the Leu 1 variant. The sample size provides 80% power to detect a difference, at a significance level of 0.05.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Kenneth E. Thummel, PhD
- Phone Number: 205-543-0819
- Email: thummel@uw.edu
Study Locations
-
-
Oregon
-
Portland, Oregon, United States, 97239-3098
- Recruiting
- Oregon Health & Science University
-
Contact:
- Bert B. Boyer, PhD
- Phone Number: 503-494-3368
- Email: boyerbe@ohsu.edu
-
Contact:
- Scarlett Hopkins, RN, MA
- Phone Number: 503-494-3369
- Email: hopkisca@ohsu.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- No history of significant medical conditions including cardiac, pulmonary, gastrointestinal, or renal disease, HIV, or history of asthma, urticaria, or allergic-type reactions with aspirin (ASA) or other NSAID (nonsteroidal anti-inflammatory drug).
- Both males or females 18 years and older.
- Self-identified as Yup'ik or Cup'ik
- Able to read and understand English or Yup'ik.
- Able to provide informed consent.
- Women not currently pregnant or lactating.
Exclusion Criteria:
- Individuals with any significant chronic medical condition, including cardiac, pulmonary, hepatic, gastrointestinal, or renal disease, HIV, or history of asthma, urticaria, or allergic-type reactions with aspirin (ASA) or other NSAID
- Individuals less than 18 years of age.
- Individuals unable to read and understand English or Yup'ik.
- Individuals unable to provide informed consent.
- Individuals taking drugs or natural products known to affect the metabolic activity of CYP2C9 (e.g., rifampin, carbamazepine, barbiturates, phenytoin, valproic acid, fluconazole, ketoconazole, miconazole, amiodarone, fluvastatin and milk thistle.
- Women who are pregnant or lactating.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Naproxen Tablet
Subjects will received a single 220-mg dose of naproxen sodium (Aleve) by mouth.
|
For this single intervention arm, each subject will receive a single 220-mg dose of naproxen sodium (Aleve), followed by urine collection for 24-hours.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
6-O-desmethyl naproxen/naproxen ratio
Time Frame: 24-hours
|
A ratio of the total mount of 6-O-desmethyl naproxen/unchanged naproxen in 24-hour urine
|
24-hours
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Kenneth E. Thummel, PhD, University of Washington
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Gout Suppressants
- Naproxen
Other Study ID Numbers
- SITE00000671
- 5P01GM116691 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pharmacogenetics
-
Duke UniversityNational Institute of General Medical Sciences (NIGMS)Completed
-
University of British ColumbiaGlaxoSmithKline; Merck Sharp & Dohme LLC; Pfizer; Roche Pharma AG; AstraZeneca; Janssen... and other collaboratorsCompleted
-
Hospital Clinic of BarcelonaFundacion Clinic per a la Recerca Biomédica; Fundació Institut de Recerca de... and other collaboratorsUnknown
-
IRCCS Burlo GarofoloRecruitingPharmacogenetics | Newborn | FentanylItaly
-
Chonnam National University HospitalInstitute of Bioequivalence and Bridging Study, College of Pharmacy, CNUCompletedPharmacogenetics | Therapeutic EquivalencyKorea, Republic of
-
Duke UniversityCompletedPharmacogenetics | Medication Therapy ManagementUnited States
-
Peter MacCallum Cancer Centre, AustraliaUniversity of AdelaideRecruiting
-
Universidad San JorgeRoche DiagnosticsCompletedPharmacogenetics | Anticoagulant | Medication Therapy Management | Community Pharmacy Services | Drug Utilization ReviewSpain
-
Hospital Italiano de Buenos AiresCompleted
-
University of Southern DenmarkRegion of Southern DenmarkCompletedPharmacogenetics of MetforminDenmark
Clinical Trials on Naproxen tablet
-
Johnson & Johnson Consumer Inc., McNeil Consumer...CompletedPost-operative Dental PainUnited States
-
GlaxoSmithKlineCompleted
-
Johnson & Johnson Consumer Inc., McNeil Consumer...Completed
-
Bispebjerg HospitalCompletedInflammation | Tendon Injuries | Achilles TendinopathyDenmark
-
Planned Parenthood League of MassachusettsCompleted
-
Johnson & Johnson Consumer Inc., McNeil Consumer...Completed
-
Eurofarma Laboratorios S.A.Recruiting
-
BayerCompletedPain, PostoperativeUnited States
-
Chinese Academy of Medical Sciences, Fuwai HospitalUnknownPulmonary Hypertension | COPDChina